RNS Number : 3857H


06 April 2022

GENinCode Plc

("GENinCode" or the "Company")

Director appointment

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the appointment to the Board of Felix Frueh , PhD ("Felix") as a Non-Executive Director.

Felix is a senior life sciences executive with in-depth expertise in corporate, regulatory, and commercialisation strategies, with a particular focus on precision medicine. He has over 25 years of experience setting scientific and corporate strategy in precision medicine, and has founded several start-ups in the diagnostics and pharmaceutical sectors. He has worked in the regulatory space for 18 years, including five years working with the FDA.

In addition to his FDA career, Felix oversaw the creation and operations of the world's largest next-generation, Clinical Laboratory Improvement Amendments (CLIA)-certified, whole human genome sequencing laboratory, as the Chief Scientific Officer of Human Longevity (HLI). Prior to this, he served as President of Medco Research Institute, Research Director for Pharmacogenetics of Transgenomic, and Assistant Director of Protogene Laboratories. He is Founder and Executive Partner of Opus Three, Co-Founder and Partner of Profound Ventures, and Co-Founder and Chief Scientific Officer of Selva Therapeutics. He also co-founded and formerly served as the Chief Executive Officer of Intellos Health.

Felix received his PhD in biochemistry from the University of Basel in Switzerland and completed postdoctoral fellowships at the University of Basel and Stanford University. He has served as a consultant, strategic advisor, and Board member to numerous diagnostic, pharmaceutical, and other healthcare companies. He is the author of more than 100 peer-reviewed articles, book chapters, white papers, market analyses, strategies, and business plans.

Matthew Walls, CEO of GENinCode Plc commented : " We are delighted that Felix is joining as a Non-Executive Director. Felix can offer us invaluable insights into the FDA as we start to look towards commericalisation in the US later this year, and his many years of experience in key roles in the industry will be a huge benefit to us. His depth of knowledge in precision medicine and regulatory affairs is second-to-none and we are looking forward to capitalising on his expertise."

Bill Rhodes, Non-Executive Chairman of GENinCode Plc, commented: "Our goal is to improve the current standard of care in cardiovascular disease worldwide through our unique portfolio of products, and Felix has the experience and expertise to help us achieve this. I am looking forward to working with him, as is the entire GENincode team, and welcome him to the Board."

Felix Frueh , PhD added: "I am thrilled to have been asked to join the Board of GENinCode at this critical stage. I have spent most of my career in the precision medicine space and feel I can add real value to the team."

Regulatory disclosures

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Felix Wilhelm Frueh, aged 54:

 Current Directorships     Previous Directorships 
 Opus Three Partners LLC   Intellos Health LLC 
  Selva Therapeutics        Enterome SA 
  Bloom Science, Inc.       Ariana Pharmaceuticals SA 

As of the date of this announcement, Felix Frueh holds no ordinary shares in the capital of the Company. Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For more information visit www.genincode.com

 GENinCode Plc                                        www.genincode.com or via Walbrook PR 
 Matthew Walls, CEO 
 Paul Foulger, CFO 
 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)          Tel: +44 (0)20 7710 7600 
 Alex Price / Ben Maddison / Richard Short 
 Cenkos Securities Plc (Joint Broker)                             Tel: +44 (0)20 7397 8900 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 Walbrook PR Limited                                                 Tel: 020 7933 8780 or 
 Anna Dunphy / Paul McManus / Louis Ashe-Jepson                   genincode@walbrookpr.com 

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

About Cardiovascular Disease

Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity. These "intermediate risks factors" can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.

Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviours.

Identifying those at highest risk of CVDs and ensuring they receive appropriate treatment can prevent premature deaths. Access to noncommunicable disease medicines and basic health technologies in all primary health care facilities is essential to ensure that those in need receive treatment and counselling.

CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas and is the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.

Genetic risk assessment can help early detection and treatment of CVD to help patients live longer, healthier lives. Many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to identify and diagnose people routinely knowing their 'ABC' (testing and monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year plan.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

April 06, 2022 02:01 ET (06:01 GMT)

Genincode (LSE:GENI)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Genincode Charts.
Genincode (LSE:GENI)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Genincode Charts.